Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/09/2860241/0/en/RAPT-Therapeutics-Announces-Promising-Results-from-Phase-2-Trial-of-Tivumecirnon-in-Combination-with-Anti-PD-1-Immunotherapy-in-CPI-Experienced-Head-and-Neck-Cancer-Patients.html
https://www.globenewswire.com//news-release/2024/03/07/2842189/0/en/RAPT-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html
https://www.globenewswire.com//news-release/2024/03/05/2840939/0/en/RAPT-Therapeutics-Announces-Multiple-Late-Breaking-Presentations-at-the-Upcoming-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html
https://endpts.com/fda-pauses-rapt-therapeutics-immunology-drug-studies-after-patient-experiences-liver-failure/
https://www.globenewswire.com//news-release/2024/02/20/2831721/0/en/RAPT-Therapeutics-Announces-Clinical-Hold-on-Studies-Evaluating-Zelnecirnon.html
https://www.globenewswire.com//news-release/2024/02/13/2828209/0/en/RAPT-Therapeutics-Bolsters-Leadership-Team-with-the-Appointment-of-Nipun-Davar-Ph-D-as-Senior-Vice-President-of-Technical-Operations.html
https://www.marketwatch.com/story/rapt-therapeutics-stock-plunges-as-fda-halts-two-clinical-trials-c484f517
https://www.globenewswire.com/news-release/2024/01/31/2821068/0/en/RAPT-Therapeutics-to-Participate-in-the-Guggenheim-Healthcare-Talks-6th-Annual-Biotechnology-Conference.html
https://www.globenewswire.com//news-release/2024/01/02/2802642/0/en/RAPT-Therapeutics-to-Present-at-the-42nd-Annual-J-P-Morgan-Healthcare-Conference.html
https://www.globenewswire.com//news-release/2023/11/27/2786122/0/en/RAPT-Therapeutics-Announces-Publication-of-Phase-1a-1b-Clinical-Trial-of-Zelnecirnon-RPT193-to-Treat-Atopic-Dermatitis-in-Allergy.html